In research published in Developmental Medicine & Child Neurology, investigators have developed a brief, reliable, and valid ...

Commercial launch in Switzerland anticipated in H2 2026Pratteln, Switzerland, January 15, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces ...

The Muscular Dystrophy Association (MDA) is proud to announce the recipients of the 2026 MDA Legacy Awards, recognizing excellence in scientific and clinical research and saluting outstanding ...

Solid Biosciences (SLDB) stock rises as a Phase 1/2 trial for its lead asset SGT-003 in Duchenne muscular dystrophy reaches ...

A rare and fatal form of muscular dystrophy has long posed a devastating diagnosis for children, primarily affecting boys. This genetic condition robs them of their ability to walk, breathe and live ...

Recent studies have defined a group of muscular dystrophies, now termed the dystroglycanopathies, as novel disorders of glycosylation. These conditions include Walker–Warburg syndrome, ...

Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular diseases that can be evident from the ...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 29th International Annual ...

The muscular dystrophies are characterized by progressive weakness and wasting of striated muscle and are caused by inherited or de novo gene mutation of sarcolemma-associated proteins or nuclear ...

New Evrysdi five-year data from the SUNFISH study showed continued stabilisation of motor function in a broad population of individuals with Types 2 or 3 spinal muscular atrophy (SMA) Late-breaking ...

DelveInsight’s “Facioscapulohumeral Muscular Dystrophy Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in the Facioscapulohumeral Muscular ...